methdilazine

Trade name: tacaryl

Small moleculeapproved

Approved

Jun 1, 1960

Methdilazine is a phenothiazine compound with antihistaminic activity. Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Jun 1, 1960

    Squibb — Earliest FDA Approval

  2. Jun 1, 1960

    Squibb — NDA Organization

1980s

  1. Jul 9, 1981

    Alpharma — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedJun 1, 1960

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCC(CN2c3ccccc3Sc3ccccc32)C1
Mol. weight
296.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine
  • methdilazine hcl
  • methdilazine hcl
  • methdilazine hcl
  • methdilazine hydrochloride
  • methdilazine hydrochloride
  • methdilazine hydrochloride
  • methdilazine hydrochloride
  • methdilazine hydrochloride
  • methdilazinum
  • methdilazinum
  • metodilazina
  • metodilazina
  • tacaryl
  • tacaryl
  • tacaryl

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
AlpharmaFor profitMKTGJul 9, 1981
SquibbFor profitNDAJun 1, 1960